Objectives: To describe haemodynamic resuscitation practices in ED patients with suspected sepsis and hypotension. Methods: This was a prospective, multicentre, observational study conducted in 70 hospitals in Australia and New Zealand between September 2018 and January 2019. Consecutive ume/earlier vasopressor and liberal fluid/later vasopressor strategy.
adults presenting to the ED during a 30-day period at each site, with suspected sepsis and hypotension (systolic blood pressure <100 mmHg) despite at least 1000 mL fluid resuscitation, were eligible. Data included baseline demographics, clinical and laboratory variables and intravenous fluid volume administered, vasopressor administration at baseline and 6-and 24-h post-enrolment, time to antimicrobial administration, intensive care admission, organ support and inhospital mortality. Results: A total of 4477 patients were screened and 591 were included with a mean (standard deviation) age of 62 (19) years, Acute Physiology and Chronic Health Evaluation II score 15.2 (6.6) and a median (interquartile range) systolic blood pressure of 94 mmHg (87-100). Median time to first intravenous antimicrobials was 77 min (42-148). A vasopressor infusion was commenced within 24 h in 177 (30.2%) patients, with noradrenaline the most frequently used (n = 138, 78%). A median of 2000 mL (1500-3000) of intravenous fluids was administered prior to commencing vasopressors. The total volume of fluid administered from pre-enrolment to 24 h was 4200 mL (3000-5661), with a range from 1000 to 12 200 mL. Two hundred and eighteen patients (37.1%) were admitted to an intensive care unit. Overall in-hospital mortality was 6.2% (95% confidence interval 4.4-8.5%). Conclusion: Current resuscitation practice in patients with sepsis and hypotension varies widely and occupies the spectrum between a restricted vol-Introduction Hypotension in sepsis results from a variable combination of fluid extravasation, peripheral vasodilatation and myocardial depression. 1 A cornerstone of immediate management is the administration of intravenous (IV) fluid, followed by commencement of a vasopressor infusion if hypotension and/or poor end-organ perfusion persists. In the absence of high-quality evidence to support specific fluid volumes, a 30 mL/kg or greater IV fluid bolus is recommended by the Surviving Sepsis Campaign. 2 However, the evaluation of a protocolised sepsis care bundle in almost 50 000 patients did not find any association between administration of 30 mL/kg IV fluid within 3 h of ED presentation, and differential mortality. 3 Despite the almost universal clinical acceptance of fluid administration in sepsis, there are multiple studies that suggest possible harm from the liberal use of this intervention. [4] [5] [6] [7] [8] [9] [10] As these studies were conducted in intensive care settings, 4, 5 conducted in lowincome countries, [6] [7] [8] or involved preclinical models, 10 their findings cannot be generalised to adults presenting to the ED with suspected sepsis in Australia and New Zealand. Indeed, an alternative approach to sepsis resuscitation is earlier initiation of vasopressor infusions, with observational studies reporting increased mortality when this is delayed. 11, 12 Moreover, a recent single centre double-blind randomised controlled trial conducted in a tertiary hospital in Thailand demonstrated that administration of lowdose noradrenaline resulted in greater shock resolution by 6 h, as compared with placebo (75 vs 48%). 13 Accordingly, the optimal volume and timing of fluid resuscitation and initiation of vasopressor support in patients with sepsis and hypotension represent significant knowledge gaps. [14] [15] [16] A comprehensive understanding of current resuscitation practices is essential for the design and conduct of future large-scale clinical trials evaluating the effects of alternative strategies (such as restricted fluid therapy combined with early vasopressor use), in patients presenting to the ED with septic shock.
As such, the aim of the Australasian resuscitation in sepsis evaluation: Fluid or vasopressors in ED sepsis (ARISE FLUIDS) observational study was to describe current resuscitation practices and outcomes in patients presenting to the ED with sepsis, specifically to determine: (i) current IV fluid and vasopressor administration; (ii) in-hospital mortality and receipt of organ support; and (iii) the incidence of patients presenting to the ED with sepsis and hypotension.
Methods

Design, setting and participants
The methodology of the ARISE FLUIDS observational study has been published previously, 17 and was endorsed by the Australasian
Key findings
• The optimal volume and timing of fluid resuscitation and initiation of vasopressor support in patients with sepsis and hypotension is unknown. • Current resuscitation practices in patients with sepsis and hypotension vary widely in our study, with fluid volume given in the first 24 hours ranging from 1-12 L. • This study will inform the design of a randomised controlled trial comparing a restricted volume (earlier vasopressor) to a liberal fluid (later vasopressor) strategy. 
Screening, data collection and follow-up
All sites were provided with a preformatted screening form and standardised education material to optimise screening, identification of eligible patients and data collection. For patients meeting all study entry criteria ( Fig. 1 ), a detailed case report form was completed. 17 
Statistical analysis
We did not perform a formal sample size calculation as this was a descriptive study. The analysis plan anticipated data collection on 400 patients. 17 Continuous variables are reported as mean and standard deviation (SD) or median and interquartile range (IQR) and categorical variables as proportions (%) as appropriate. Baseline characteristics, process-of-care measures (e.g. fluid volume at 6-and 24-h post-enrolment and frequency, timing and duration of vasopressor administration) and outcomes (e.g. ED disposition, ICU admission, receipt and duration of organ support and in-hospital mortality) are reported. Subgroups based on pre-enrolment characteristics were specified a priori: (i) hospital type (rural/regional, metropolitan/district, private, tertiary); (ii) age <65 versus ≥65 years; (iii) quartiles of the Acute Physiology and Chronic Health Evaluation (APACHE II) score at T0; (iv) presence of cardiovascular disease; (v) SBP <90 versus ≥90 mmHg; (vi) lactate <2.0 versus ≥2.0 mmol/L; (vii) SBP <90 mmHg and lactate ≥2.0 mmol/L and first dose of IV antimicrobials commenced patients versus patients not meeting these criteria; (vi) source of sepsis; abdominal source versus other; respiratory source versus other; (vii) quartiles of fluid volume administered up to 6 h post-enrolment; and (viii) quartiles of time to commencing a vasopressor infusion. Betweengroup differences in in-hospital mortality, ICU admission and receipt and duration of organ support were compared for the quartiles of volume of fluid administered and quartiles of time to commencing vasopressors sub-groups. Chi-squared or Fisher's exact test for categorical variables were used and Student's t-test or Mann-Whitney U-test used for continuous variables.
Results
The 70 participating EDs had a combined adult patient attendance during their respective 30-day data collection periods of 295 904 patients. Of 4477 patients screened, 591 (13.2%) patients met the eligibility criteria for detailed data collection ( Fig. 1 ). 
Baseline characteristics
Baseline characteristics are summarised in Table 1 . The mean (SD) age was 62.4 (19.1) years and APACHE II score 15.2 (6.7). The median time from ED presentation to commencing IV antimicrobials was 77 (IQR 42-148) minutes. More than one-third (37.6%, n = 222) had no prior co-morbidities and 9.8% (n = 58) lived in a residential care setting. Table S1 portrays vital signs, blood gas analyses, receipt of invasive ventilation and laboratory data at baseline, 6, and 24 h. (Table S2 ). Almost one-third of patients (30.2%, n = 177) received a vasopressor infusion in the first 24 h post-enrolment, with noradrenaline (78%, n = 138) and metaraminol (42%, n = 74) most frequently used (Table 3 ). In patients with a SBP <90 mmHg at baseline, 48.4% (n = 92) received a vasopressor infusion up to 24 h post-enrolment and in patients with a SBP <90 mmHg and a lactate ≥2 mmoL/L, almost twothirds (64.6%, n = 53) received a vasopressor. A central venous catheter or peripherally inserted central catheter were inserted in the first 24 h in 126 patients (21.5%).
Fluid resuscitation and vasopressor therapy
Clinical outcomes
Overall, one-third (33.7%, n = 198) of patients had a respiratory source and a quarter (25.0%, n = 147) had a urinary source, with no source found in 10.2% (n = 60). The median ED length of stay was 7.9 h (5.4-13.4) and over one-third (37.1%, n = 218) of patients were admitted to an intensive care setting in the first 24 h. ICU admission rates were higher for the 
Subgroup analyses by fluid volume and time to vasopressor infusion
Pre-specified sub-group analyses are provided in Tables S3-S11. Tables 4,5 show the clinical outcomes according to the volume of fluid administered in the 6 h post-enrolment and the timing of commencing a vasopressor infusion. The highest fluid quartile received more than 5 times the fluid volume as the lowest quartile in the first 6 h post-enrolment (3612 vs 689 mL) and twice as much in the first 24 h (6600 vs 3011 mL). Between quartile 1 and quartile 4, there was an increase in vasopressor initiation (from 19.1 to 47.6%), ICU admission (from 23.9 to 60%) and receipt of invasive ventilation (from 9.1 to 22.1%) ( Table 4 ). Duration of vasopressor therapy varied between 17.5 and 24.5 h in the lowest three fluid quartiles and was 36 (IQR 22-69) hours in the highest fluid quartile. Although in-hospital mortality was similar across all fluid quartiles, duration of hospital stay was 4.5 days in quartile 1 and 7.0 days in quartile 4.
The quartile of patients who commenced a vasopressor infusion the earliest (within 2.7 h of ED presentation) tended to be older and tended to have a higher baseline lactate and APACHE II score as well as a lower SBP compared to the remaining quartiles ( Table 5 ). The total volume of fluid administered between 0 and 6 h and up to 24 h was similar across the vasopressor quartiles, although the quartile of patients who received vasopressors the latest (after 7.71 h), were given most fluid (3500 mL [3000-4100]) prior to commencement of vasopressors. The in-hospital mortality for patients receiving vasopressors was 13.1% (n = 23) with a median hospital length of stay of 8.6 (4.4-18) days.
Discussion
Key findings
Our study provides critical contemporary data concerning sepsis resuscitation in EDs throughout Australia and New Zealand. Namely, patients received on average 2 L of IV fluid in the first 6 h after enrolment, and 4.5 L in the first 24 h in hospital (including pre-enrolment). Approximately 30% required vasopressor support within the first 24 h, after a median of 2 L of IV fluid, and 4.7 h from ED triage. A SBP <90 mmHg and/or lactate ≥2 mmoL/L was associated with greater fluid administration, more frequent use of vasopressors, and higher rates of admission to ICU. Patients receiving larger volume fluid resuscitation more commonly needed vasopressors and mechanical ventilation, and had a longer hospital stay. Overall, in-hospital mortality was low (6.2%).
Comparison with other studies
The routine care arms in the ARISE Early Goal Directed Therapy 19 and Restricted Fluid Resuscitation in Sepsis associated Hypotension (REFRESH) 20 randomised controlled trials delivered different fluid volumes from preenrolment to 6 h post (4.2 vs 3 L). This may reflect differences in severity of disease or inclusion criteria, but could also suggest adoption of a more fluid restrictive approach over time. The routine care group in REFRESH received a median of 1715 mL between 0 and 6 h and 4250 mL from pre-enrolment to 24 h, which is similar to the overall findings in the current study. The quartile of patients receiving the lowest fluid volume (median 900 mL administered in the first 6 h after enrolment and 3 L in the first 24 h), had somewhat less fluid administered than the restricted volume arm of REFRESH. 20 In contrast, the quartile of patients in our study receiving the most fluid were administered 3.2 L in the first 6 h after enrolment and 5.4 L from preenrolment to 24 h, with the overall range of fluid given in the first 24 h varied between 1 and 12.2 L. These findings are consistent with sepsis being a highly variable clinical syndrome, where an individualised approach to fluid resuscitation is often employed.
Of note was the low in-hospital mortality observed in the present study (6.2%, 95% confidence interval 4.5-8.5%), whereas other Australasian studies of patients with sepsis and hypotension have reported inhospital mortality rates between 18 and 25%. 21, 22 In contrast, and consistent with our study, when assessing patients without limitations of care, the 30-day mortality was 6.2% in a cohort of 399 ED patients with septic shock in a tertiary hospital in Australia. 21 Temporal improvements of sepsis care and an associated decrease in mortality in Australia and New Zealand may also partially explain our findings. 22 Our study used a similar methodology to that undertaken in 32 Australian and New Zealand hospitals conducted in 2009. 23 However, the inclusion criteria for that study were a SBP <90 mmHg despite a 500 mL bolus or a lactate greater than 4 mmol/L. Notably, all patients with sepsis were included in the 2009 study, whereas in our study patients with limitations of care were excluded. These differences in eligibility may explain the higher APACHE II score in the 2009 study compared to ARISE FLUIDS (19 AE 8.2 vs 15.2 AE 6.7) as well as the higher mortality (23.1%). In ARISE 2009, approximately 2 L was administered between 0 and 6 h, which was similar to ARISE FLUIDS. Almost one-third (32%) of patients received vasopressors in the first 6 h after enrolment in ARISE 2009, whereas in ARISE FLUIDS a similar proportion had vasopressors started before 24 h (30.2%). The median time to vasopressor commencement was 4.6 h (2.7-7.8) which was shorter than median time to central line access of 6.5 h (3.5-10.1), indicating vasopressor delivery through a peripheral line occurred. This practice is supported by an analysis of patients who received peripheral vasopressors in the ARISE Early Goal Directed Therapy trial 19 which showed that this was associated with some improvements in processes of care, and not associated with differential mortality. 24 A recent systematic review concluded when given for a limited duration and under close observation, adverse events of peripheral vasopressors are rare. 25 
Study implications
Our study found significant heterogeneity in fluid volume resuscitation in hypotensive patients with sepsis, implying that the clinical environment might potentially support a controlled trial in this area. 26 With falling mortality among patients with sepsis who are eligible for ICU care, there is a growing recognition that long-term quality of life among survivors relates to organ failure. 27, 28 In this respect, our data suggest a potential relationship between greater fluid volume resuscitation in the first 6 and 24 h and organ dysfunction, implying that the need for invasive organ support represents a logical endpoint for future work. Finally, our study provided important insights into the yield of our screening procedures. One in every 66 adult ED presentations (1.51%) were screened with an enrolment rate of 13.2%, or a 'number needed to screen' of 7.6. This corresponded with 2 in every 1000 adult attendances in the present study being eligible, which is consistent with prior research. 29 
Limitations
The participating sites were selfselected based on an expression of interest via the Australasian College for Emergency Medicine, with data collection occurring only in spring and summer. However, the 70 hospitals represented a wide geographical spread ranging from tertiary to rural and remote facilities with varying levels of onsite ICU facilities. As such we believe our findings have robust external validity. Although in-hospital mortality is lower in this study than most others performed in similar settings, comparisons are difficult to make, as compared to other studies we did not report 90-day mortality. This was because we utilised an endpoint more proximal to the exposure of interest (e.g. fluid administration in ED), as 90-day mortality is likely to be confounded by other factors. We excluded 26 patients where death was imminent and 33 with a life-expectancy <90 days.
It is possible that not all patients were screened or enrolled. In particular, the low mortality rate raises the question as to whether sicker patients were missed. A more likely explanation is that patients who were not eligible for ICU admission were excluded from our study, particularly since we had dedicated site clinician-investigators actively screening for suitable patients. In the Australasian ED setting these patients not eligible for ICU admission represent a substantial proportion of patients who die as a result of their sepsis, with mortality rates varying between 47 and 66%. 22, 23 Further, missing data were inevitable as patients received routine care which may not include all relevant variables. Any 'missingness' is therefore likely to be random.
The observation that an increasing volume of fluid was associated with a greater proportion requiring vasopressors and/or mechanical ventilation should be viewed cautiously. Although greater fluid administration has been associated with harm, this is clearly confounded by illness severity. In this respect, these data should be considered hypothesis-generating at best, and reinforces the need for future systematic research in this area.
Conclusion
The ARISE FLUIDS observational study is the largest Australasian observational study providing a 30-day snapshot of contemporary ED practice across a wide range of settings, from rural/regional to metropolitan teaching hospitals. Current resuscitation practices in patients with sepsis and hypotension in Australia and New Zealand vary widely, occupying the spectrum between a restricted volume/earlier vasopressor and liberal fluid/later vasopressor strategy.
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